Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Fair Market Value

<< Previous

Bullboard Posts

Next >>

Comment by lonc17on Dec 15, 2023 3:18pm

130 Views

Post# 35787324

RE:RE:Fair Market Value

I'm so far underwater on my original investment that there is no point in selling. I may as well hold on and see if it works as a lottery ticket.

I follow ONC (for 25 years) because I like the science and I believe OV's could be widely approved someday.

But ONC as a company is worth very little with the current management team. I post warnings as a public service to younger investors who may consider swinging for the fences with an investment in ONC.

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for Oct. 1, 2024